|CL413 VacciGrade™||Unit size||Cat. code||Docs||Qty||Price|
TLR2 & TLR7-based adjuvant
Dual TLR2 & TLR7 agonist
CL413 is a chimeric molecule that co-activates the surface receptor TLR2 and the endosomal receptor TLR7. It is composed of 8-hydroxyadenine (TLR7 ligand) conjugated to the terminal acid function of Pam2CSK4 (TLR2 ligand). CL413 is water soluble.
This chimeric compound displays strong adjuvant activity. In mice, administration of OVA with CL413 leads to a significant increase of anti-OVA IgG titers in sera. The predominant IgG subclass is IgG1, a Th2-associated isotype. The IgG2a subclass, a Th1-associated isotype, is also significantly increased resulting in a decreased IgG1/IgG2a ratio.
CL413 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
CL413 VacciGrade™ is for research use only, not for use in humans.Back to the top
Description: TLR2 & TLR7 VacciGrade™ Agonist
Synonym: S-(2,3-bis(palmitoyloxy)-(2RS)propyl)-(R)-cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysyl 4-((6-amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)aniline
Molecular weight: 1581
Solubility: 1 mg/ml in physiological water
Endotoxin Level: Lower than 5 EU/mg
Working concentration: 20 - 50 µg/mouseBack to the top
- 5 mg CL413 VacciGrade™
- 10 ml of sterile endotoxin-free physiological water (NaCl 0.9%)
CL413 VacciGrade ™ is shipped at room temperature.
Store lyophilized product at -20 °C.
Lyophilized product is stable for 1 year at -20 °C.Back to the top
InvivoGen has developed a series of novel molecules designed to induce potent immune responses through the combined activation of several pattern recognition receptors (PRRs) that trigger different innate immune signaling pathways.
These molecules are agonists for TLR2, TLR7 or both. Agonists that activate TLR2 are derived from the well-established TLR2 ligand, Pam2CSK4, and those recognized by TLR7 are derived from the 8-hydroxyadenine derivative CL264, a TLR7 agonist recently developed by InvivoGen.
TLR2 and TLR7 are two PRRs with distinct characteristics. TLR2 is a cell surface receptor expressed by many cell types, while TLR7 is an endosomal receptor expressed predominantly in plasmacytoid dendritic cells (pDC) and to a lesser extent in B cells.
TLR2 signaling triggers the NF-kB pathway and the production of pro-inflammatory cytokines, such as TNF-α, whereas TLR7 signaling induces mainly the IRF pathway and the production of IFN-α.Back to the top
Back to the top